{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T09:14:24Z","timestamp":1764494064818,"version":"3.41.2"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai","doi-asserted-by":"publisher","award":["No. 19ZR1410400"],"award-info":[{"award-number":["No. 19ZR1410400"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.01116","type":"journal-article","created":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T04:30:41Z","timestamp":1571718641000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center"],"prefix":"10.3389","volume":"9","author":[{"given":"Chang","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianqian","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiquan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weixin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuaile","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengfei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhua","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,10,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1053\/j.seminoncol.2017.02.003","article-title":"Screening for lung cancer","volume":"44","author":"Sateia","year":"2017","journal-title":"Sem Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1200\/JCO.2012.44.5353","article-title":"ALK in lung cancer: past, present, and future","volume":"31","author":"Shaw","year":"2013","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK","volume":"27","author":"Shaw","year":"2009","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12885-017-3720-8","article-title":"Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment","volume":"18","author":"Zhou","year":"2018","journal-title":"BMC Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1080\/14656566.2016.1242578","article-title":"Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice","volume":"17","author":"Caccese","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1470-2045(12)70344-3","article-title":"Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study","volume":"13","author":"Camidge","year":"2012","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e000219","DOI":"10.1136\/esmoopen-2017-000219","article-title":"Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced\/metastatic ALK-positive non-small-cell lung cancer","volume":"2","author":"Blackhall","year":"2017","journal-title":"ESMO Open"},{"key":"B9","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/14737140.2018.1412260","article-title":"Targeted therapies in non-small cell lung cancer: a focus on ALK\/ROS1 tyrosine kinase inhibitors","volume":"18","author":"Sgambato","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e443","DOI":"10.1200\/JCO.2010.34.1313","article-title":"CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib","volume":"29","author":"Costa","year":"2011","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S1470-2045(15)00013-3","article-title":"Targeting brain metastases in ALK-rearranged non-small-cell lung cancer","volume":"16","author":"Zhang","year":"2015","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","article-title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","article-title":"Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study","volume":"29","author":"Novello","year":"2018","journal-title":"Ann Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S1470-2045(16)30392-8","article-title":"Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1\/2 trial","volume":"17","author":"Gettinger","year":"2016","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1002\/cncr.24181","article-title":"The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS","volume":"115","author":"Wong","year":"2009","journal-title":"Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/1759-7714.13050","article-title":"Favorable predictors for survival in advanced ALK-positive non-small cell lung cancer patients beyond crizotinib resistance","volume":"10","author":"Xu","year":"2019","journal-title":"Thorac Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s11523-019-00637-5","article-title":"Efficacy of crizotinib for advanced ALK-rearranged non-small-cell lung cancer patients with brain metastasis: a multicenter, retrospective study in China","volume":"14","author":"Xing","year":"2019","journal-title":"Targeted Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1158\/0008-5472.CAN-16-3072","article-title":"Circulating tumor cells with aberrant ALK copy number predict progression-free survival during crizotinib treatment in ALK-rearranged non-small cell lung cancer patients","volume":"77","author":"Pailler","year":"2017","journal-title":"Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1200\/JCO.2015.62.0138","article-title":"Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis","volume":"34","author":"Johung","year":"2016","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.canlet.2019.04.034","article-title":"Malignant ascites-derived exosomes promote peritoneal tumor cell dissemination and reveal a distinct miRNA signature in advanced gastric cancer","volume":"457","author":"Hu","year":"2019","journal-title":"Cancer Lett"},{"key":"B27","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S2213-2600(19)30053-0","article-title":"Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study","volume":"7","author":"Zhou","year":"2019","journal-title":"Lancet Respiratory Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1093\/annonc\/mdy292.002","article-title":"Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study","volume":"14","author":"Camidge","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"5093","DOI":"10.2147\/OTT.S165511","article-title":"Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date","volume":"11","author":"Akamine","year":"2018","journal-title":"Onco Targets Ther"},{"key":"B30","doi-asserted-by":"publisher","first-page":"141","DOI":"10.21037\/atm.2017.11.34","article-title":"Treating ALK-positive non-small cell lung cancer","volume":"6","author":"Ziogas","year":"2018","journal-title":"Ann Trans Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.01116\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T04:30:43Z","timestamp":1571718643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.01116\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,22]]},"references-count":30,"alternative-id":["10.3389\/fonc.2019.01116"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.01116","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2019,10,22]]},"article-number":"1116"}}